HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells
Exley, M A
Anderson, K C
Munshi, N C
MetadataShow full item record
CitationSong, W, Y-T Tai, Z Tian, T Hideshima, D Chauhan, P Nanjappa, M A Exley, K C Anderson, and N C Munshi. 2013. “HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells.” Leukemia 25 (1): 10.1038/leu.2010.244. doi:10.1038/leu.2010.244. http://dx.doi.org/10.1038/leu.2010.244.
AbstractLBH589 is a novel pan-HDAC inhibitor which has potent antitumor activity in multiple myeloma and other hematologic malignancies. However, its impact on immune system has not been defined. We here evaluated the effects of LBH589 on human myeloid dendritic cells (DCs) at clinically relevant concentrations. Exposure to LBH589 affected the surface molecule expression on immature and mature DCs, associated with DC maturation (CD83↓), antigen presentation (HLA-ABC↓), and T cell co-stimulation (CD40↓ and CD86↑). LBH589 decreased both protein and polysaccharide antigen uptake capacities by DCs. Importantly, LBH589 impaired DCs function to stimulate antigen-specific immune responses, resulting in the significant reduction of invariant NKT cell (CD1d-restricted) and T cell (MHC-restricted) activation in innate and adaptive immunity. LBH589 also significantly repressed the production of IL-6, IL-10, IL-12p70, IL-23 and TNF-α by TLR3 and TLR4-induced DCs activation, indicating an important role of HDAC activity in immune regulation and inflammation. RelB, a component of NF-κB signaling pathway, was the key component regulated by HDAC inhibition in DCs. Together, our preclinical study demonstrates that LBH589 significantly impairs phenotype and function of DCs, indicating a need for monitoring the immune status in patients receiving HDAC inhibitor therapy. It also provides a rationale to evaluate LBH589 activity for the treatment of inflammation.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879136
- HMS Scholarly Articles